Regional Medical Center Bayonet Point Participates in “Reduce MRSA Study”
May 16, 2012
Hudson, FL – Regional Medical Center Bayonet Point has announced its participation in the “Reduce MRSA” study, a landmark trial to eliminate MRSA infections in critical care environments. Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that causes infections in different parts of the body. It's tougher to treat than most strains of staphylococcus aureus -- or staph -- because it's resistant to some commonly used antibiotics.
Regional Medical Center Bayonet Point was one of 52 hospitals in 72 intensive care units in 16 states enrolled in the study. The reduce MRSA study was a collaborative effort between the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Healthcare Institute, the Center for Quality Improvement and Patient Safety, an agency of healthcare research and quality, the National Center of Emergency and Zoonotic Infectious Diseases of the Center for Disease Control & Prevention (CDC). These three agencies are in collaboration with HCA the Healthcare Company in conducting this study.
Recently Regional Medical Center Bayonet Point was awarded a certificate of appreciation in recognition and appreciation for its tremendous dedication to the creation of the scientific evidence to guide efforts to eliminate MRSA infections in the critical care environment.
Marketing & Public Relations Contact: